Ingevity (NGVT) Cash & Equivalents (2015 - 2026)

Ingevity (NGVT) has 12 years of Cash & Equivalents data on file, last reported at $95.4 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 33.43% year-over-year to $95.4 million in Q1 2026; TTM through Mar 2026 was $95.4 million, a 33.43% increase from a year earlier, with the FY2025 full-year figure at $78.1 million, up 14.85% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $95.4 million, up from $78.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NGVT reached as high as $222.6 million in Q1 2022 and fell as low as $68.0 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $96.1 million across 5 years, with a median of $83.4 million in 2025.
• Across the five-year window, Cash & Equivalents slumped 73.16% in 2022 and jumped 60.36% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $76.7 million in 2022, then grew by 25.03% to $95.9 million in 2023, then dropped by 29.09% to $68.0 million in 2024, then grew by 14.85% to $78.1 million in 2025, then increased by 22.15% to $95.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $95.4 million in Q1 2026, $78.1 million in Q4 2025, and $83.4 million in Q3 2025.